<SEC-DOCUMENT>0001062993-17-001885.txt : 20170417
<SEC-HEADER>0001062993-17-001885.hdr.sgml : 20170417
<ACCEPTANCE-DATETIME>20170414181109
ACCESSION NUMBER:		0001062993-17-001885
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170410
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170417
DATE AS OF CHANGE:		20170414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17763376

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>April 10,
2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%"><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD width="50%" align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%">(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250) 765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))<BR>[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that Lexaria and
Neutrisci International Inc. have completed and signed the previously announced
joint venture agreement is filed as exhibit 99.1 to this current report and is
hereby incorporated by reference. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Financial Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated April 10,
      2017 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%"  >&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Date: April 14, 2017 </TD>
    <TD align=left width="50%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="50%"
>&nbsp;</TD>
  </TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria and Neutrisci Enter Cannabinoid Joint Venture
</B></P>
<P align=justify>Kelowna, BC / April 10, 2017 / Lexaria Bioscience Corp
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148;) and Neutrisci International Inc
(&#147;Neutrisci&#148;) (TSX-V:NU, OTCQB:NRXCF, Frankfurt-1N9) have completed and signed
the previously announced joint venture agreement (the &#147;JV&#148;) to produce and
commercialize a line of healthy, sugar-free, edible cannabinoid mouth-melt
products which will utilize Lexaria&#146;s patented technology and Neutrisci&#146;s
proprietary pterostilbene tablet form factor.</P>
<P align=justify>The JV will be named Ambarii Trade Corporation (or similar)
(&#147;Ambarii&#148;) and the initial operations will be fully and equally funded by both
Lexaria and Neutrisci. Lexaria and Neutrisci will contribute their respective
technologies to Ambarii by way of license agreement, and share profits derived
from the JV on a 50/50 basis. While there are no immediate plans to do so,
Ambarii will be structured in such a way as to allow for a potential future
spin-off to be created which could provide value to shareholders of both Lexaria
and Neutrisci.</P>
<P align=justify>Ambarii intends to secure licensees in California, Colorado and
in Canada to manufacture and sell mouth-melt products containing THC. These
products will combine the benefits of each of Lexaria&#146;s and Neutrisci&#146;s existing
technologies and ingredient mixes. A licensed California entity is scheduled to
manufacture and test a THC version of the products in June, 2017. In more
developed legal markets such as California and Colorado, cannabis edibles often
comprise 33% - 55% market share of all legal sold cannabis products, making high
quality cannabis edibles vitally important to the marketplace. </P>
<P align=justify>Ambarii also intends to develop hemp oil based mouth-melt
products for distribution through networks including Neutrisci&#146;s existing
network of retail distributors as well as other methods. Initial test production
runs of the hemp oil variety pterostilbene based products has already achieved
positive human focus group results.</P>
<P align=justify>&#147;This JV signals a milestone advancement in the cannabis
edibles marketplace with the advent of a novel line of healthy, sugar-free
mouth-melt products,&#148; commented Chris Bunka, Lexaria CEO. &#147;Lexaria is excited to
have reached this agreement to lever its patented palatability and absorption
enhancing technology for these unique and promising new product offerings.&#148; </P>
<P align=justify>Glen Rehman, President of NeutriSci stated, &#147;We are thrilled to
officially partner with Lexaria. This Agreement represents a giant leap forward
for the development, sale and manufacturing of cannabis edibles. Ambarii will
deliver an edible product that is not only highly effective, but also a healthy
sugar free alternative with the benefits of pterostilbene. The Ambarii product
line will be a world first, and will have high appeal to today&#146;s health
conscious medicinal and recreational users.&#148; </P>
<P align=justify>Lexaria&#146;s unique patented
  technology allows for more efficient and effective absorption of certain
  molecules such as cannabinoids, while simultaneously masking and at times even
  eliminating inherent strong flavours and/or odors typical of those molecules.
  Lexaria&#146;s technology is extremely cost effective to implement and applicable to
  a wide spectrum of foods. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company&#146;s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Company&#146;s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <BR><U><FONT
color=#0000ff>www.lexariabioscience.com </FONT></U></P>
<P align=justify><B>About NeutriSci<BR></B>NeutriSci specializes in the
innovation, production and formulation of nutraceutical products. Established in
2009, NeutriSci has focused on the development of several breakthrough
nutraceutical products with an initial focus on areas such as heart and
cholesterol health, sleep deprivation therapies, immune defense as well as men's
prostate and sexual health. NeutriSci continues to build strong relationships
and distribution channels for its BluScience&#153; and NeuEnergy&#153; products with
retailers throughout the United States. NeutriSci is focusing efforts in
strengthening sustainable sales models with Convenience, Chain Drug, and Mass
Market and Supermarket retailers. <BR><U><FONT
color=#0000ff>www.neutrisci.com</FONT></U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Chris Bunka<BR>Chairman &amp; CEO<BR>(250) 765-6424 <BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that the
joint venture with Neutrisci will generate revenue nor provide any other benefit
to Lexaria, or that the Company will experience any growth through participation
in these sectors or as a result of the joint venture. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements, nor that Lexaria&#146;s technology will deliver any improvement in taste
or bioavailability with any reliability nor across any product category. There
is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPova<SUP>TM </SUP>products are not intended to diagnose, treat, cure or
prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.</I><B> </B></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
